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Abstract 
Background: More than 50,000 adult and cord blood samples were collected in Tempus tubes and stored at the 
Norwegian Institute of Public Health Biobank for future use. In this study, we systematically evaluated and compared 
five blood-RNA isolation protocols: three blood-RNA isolation protocols optimized for simultaneous isolation of all 
blood-RNA species (MagMAX RNA Isolation Kit, both manual and semi-automated protocols; and Norgen Preserved 
Blood RNA kit I); and two protocols optimized for large RNAs only (Tempus Spin RNA, and Tempus 6-port isolation kit). 
We estimated the following parameters: RNA quality, RNA yield, processing time, cost per sample, and RNA transcript 
stability of six selected mRNAs and 13 miRNAs using real-time qPCR.
Findings: Whole blood samples from adults (n = 59 tubes) and umbilical cord blood (n = 18 tubes) samples col-
lected in Tempus tubes were analyzed. High-quality blood-RNAs with average RIN-values above seven were extracted 
using all five RNA isolation protocols. The transcript levels of the six selected genes showed minimal variation 
between the five protocols. Unexplained differences within the transcript levels of the 13 miRNA were observed; 
however, the 13 miRNAs had similar expression direction and they were within the same order of magnitude. Some 
differences in the RNA processing time and cost were noted.
Conclusions: Sufficient amounts of high-quality RNA were obtained using all five protocols, and the Tempus blood 
RNA system therefore seems not to be dependent on one specific RNA isolation method.
Keywords: Tempus tubes, Cord blood, MiRNA, Noncoding RNA, Gene expression, RNA isolation, Epigenetics, The 
Norwegian Mother and Child Cohort Study, MoBa, Biobank
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Findings
Background
Blood-based biobanks such as the NIPH Biobank at 
the Norwegian Institute of Public Health (NIPH), and 
multi-center studies, increasingly incorporate studies 
identifying candidate mRNA and microRNA (miRNA) 
expression profile based biomarkers for a wide range of 
disorders. Identification of biomarkers in an easily acces-
sible and minimally-invasive biological sample such 
as blood would be a valuable complementing tool for 
diagnostics and prognostics of different types of diseases. 
The strong stability of miRNAs in circulating blood and 
their role as key regulators of almost every biological pro-
cess [1] suggests that they could serve as non-invasive 
biomarkers for a wide range of diseases [2–5]. Further-
more, miRNAs have been shown to be targeted by epi-
genetic modification, and in turn, miRNAs can target 
regulators of epigenetic pathways [6–9]. MiRNAs’ role 
in neurodevelopmental diseases, both as diagnostic bio-
markers as well as explaining basic disease etiology has 
come into focus; aberrant miRNA function has been 
linked to the etiology of several neurological disorders 
[10–15]. Recently a set of five miRNAs in blood serum 
of children with autism spectrum disorder (ASD) was 
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suggested as potential candidates for circulating miRNA-
based prediction of ASD [16].
The Norwegian Mother and Child Cohort Study 
(MoBa) is a prospective population-based pregnancy 
cohort study conducted by the NIPH. Participants were 
recruited from all over Norway from 1999 to 2008, 
and the cohort now includes more than 114,500 chil-
dren, 95,200 mothers and 75,200 fathers [17]. Biologi-
cal material in the form of whole blood and plasma has 
been collected from the mother, the father and the 
child (umbilical cord blood) and stored in the Biobank, 
together with extracted DNA, for future use [18]. In 
2005, as part of the Autism Birth Cohort (ABC) study 
with support from the National Institute of Neurologi-
cal Disorders and Stroke (NINDS), we evaluated two 
commercially available RNA stabilizing technologies for 
the collection of blood in MoBa: PAXgene Blood RNA 
system (PreAnalytix, QIAGEN/BD) and Tempus Blood 
RNA system (Life Technologies) [19]. Since 2005, more 
than 50,000 adult and cord blood samples were collected 
in the Tempus tubes and stored in the NIPH Biobank for 
future RNA isolation and downstream analyses.
Recently, we have systematically evaluated a blood-
RNA isolation protocol for blood samples collected in 
the Tempus tubes using Tempus 6-port RNA isolation kit 
(Life Technologies) on a 6100 Nucleic Acid Prep Station 
[19, 20]. This protocol is now a well-established blood-
RNA isolation protocol at the NIPH Biobank. However, 
the Tempus 6-port RNA isolation kit has some limita-
tions; in particular, it does not retain well small RNAs 
(<200 nucleotides), i.e., most of the small noncoding 
RNAs (ncRNAs) will be lost during the RNA isolation. 
Recently, the Tempus tube supplier (Life Technologies, 
Norway), and Norgen Biotek Corp (Norgen Biotek Corp, 
Canada) have introduced new blood-RNA isolation kits 
optimized for simultaneous isolation of all RNA species 
from blood samples stabilized in Tempus tubes. To make 
the NIPH Biobank more flexible and not to be dependent 
on one specific RNA isolation method, it is very impor-
tant to establish several comparable blood-RNA isolation 
protocols. Consequently, the NIPH Biobank has estab-
lished alternative blood-RNA isolation protocols capa-
ble of isolating all RNA species simultaneously from the 
blood samples collected in the Tempus tubes.
In this study, we report on the evaluation of five blood-
RNA isolation protocols: MagMAX semi-automated, 
MagMAX manual, Tempus spin, Tempus 6-port, and 
Norgen (Table  1). These protocols are optimized for 
blood samples collected in Tempus tubes. The protocols 
were evaluated and compared with regard to their suit-
ability of isolating high-quality RNA (including small 
ncRNAs) from adult and cord blood samples collected in 
Tempus tubes and stored at −80 °C at the NIPH Biobank. 
The performance of the methods, i.e. the sample process-
ing time and cost, and the possibility of (semi)-automa-
tion of the sample processing part, have to be considered 
when introducing a new RNA isolation method. Here, 
we report a systematic evaluation and comparison of 
five blood-RNA isolation protocols, with regards to RNA 
quality (i.e., purity and integrity), yield, RNA process-
ing time, cost per sample, and RNA transcript stabil-
ity of six genes (CDKN1A, FOS, IL1B, IL8, MYC, TP53) 
and 13 miRNAs (hsa-let-7a, hsa-miR-16, hsa-miR-20a, 
hsa-miR-21, hsa-miR-26a, hsa-miR-34a, hsa-miR-451, 
hsa-miR-93, hsa-miR-103, hsa-miR-126, hsa-miR-191, 
hsa-miR-192, hsa-miR-423-3p) selected based on our 
previous studies [19, 20] and literature search [21, 22]. 
Furthermore, the new protocols were compared against 
the Tempus 6-port protocol which is already a well-estab-
lished RNA isolation protocol at the Biobank [19, 20].
Results and discussion
In MoBa, the combination of biological specimens and 
questionnaire data on lifestyle and exposures provide 
unique possibilities to study the effects of many factors 
of relevance for pregnancy outcomes and health. In order 
to get more insight into the biological mechanisms trig-
gered by gene-environment interactions and disease, the 
NIPH Biobank is now incorporating blood-based mRNA 
and miRNA expression profiling studies. However, reli-
able quantification of mRNA and miRNA levels requires 
high-quality RNA, and compromised RNA integrity has 
been shown to influence the quantification of mRNA and 
miRNA levels [23–25]. Recently, we reported that intact 
and high-quality RNA suitable for mRNA profiling analy-
ses was obtained from blood samples collected in the 
Tempus tubes and stored at −80  °C, of satisfactory sta-
bility during storage over a period of up to 6 years [20]. 
However, the well-established RNA isolation protocol 
(Tempus 6-port RNA isolation kit on a 6100 Nucleic Acid 
Prep Station) at NIPH Biobank, is not optimized for iso-
lation of small RNA molecules (<200 nucleotides). There-
fore, a comparison and evaluation of several blood-RNA 
isolation protocols which may replace the well-estab-
lished Tempus 6-port protocol at the NIPH Biobank was 
conducted.
To evaluate the RNA quality and transcript stability of 
the blood-RNAs isolated using five blood-RNA isolation 
protocols (Table 1), blood samples collected in the Tem-
pus tubes and stored at −80 °C, were thawed according 
to the manufacturers’ recommendations. Total RNA was 
isolated from adult blood (n  =  59 Tempus tubes from 
four donors) and cord blood (n = 18 Tempus tubes from 
six donors) samples using the five RNA isolation proto-
cols. For each blood-RNA isolation protocol, 11–12 Tem-
pus tubes containing adult blood and 3–6 Tempus tubes 
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containing cord blood were analyzed. The RNA yield and 
purity were measured by spectroscopic quantification 
using NanoDrop ND-8000 Spectrophotometer. The RNA 
integrity, expressed as RIN values, was assessed using an 
Agilent 2100 Bioanalyzer, and the transcript stability for 
six target mRNAs and 13 target miRNAs were analyzed 
by real-time qPCR assay.
The average total RNA yield for the adult and cord 
blood samples of the five RNA isolation protocols were 
15.4 ± 4.2 and 90.8 ± 23.6 μg per Tempus tube, respec-
tively (Fig.  1). No significant differences in the average 
RNA yield between the five protocols were observed 
from adult blood samples (Fig. 1). Similar to our previous 
reports [19, 20], the RNA yields obtained from the cord 
blood samples were significantly higher than the RNA 
yield obtained from the adult blood samples (Fig. 1). For 
cord blood samples, statistically significantly higher RNA 
yields were obtained from blood samples isolated using 
the two MagMAX (semi-automated and manual) pro-
tocols (p < 0.05), compared to the other three protocols 
(Fig. 1). The reason for this is unknown but may be due to 
the RNA isolation technology using magnetic beads for 
capturing the RNA. However, no such protocol-related 
difference was observed for adult blood. The amounts 
of RNA obtained from both adult and cord blood sam-
ples from all five protocols were within the range of RNA 
yields reported previously [20, 26], and the obtained 
yields of RNA were sufficient for downstream analysis.
The integrity and purity of RNA can be used to evalu-
ate the performance of the RNA isolation protocols. RNA 
with an OD 260/280 ratio >1.9 are generally accepted as 
pure RNA suitable for gene expression analyses [27], and 
OD 260/230 ratio <1.8 generally indicates the presence of 
contaminants. The OD 260/280 and OD 260/230 ratios of 
the isolated total RNA from adult and cord blood sam-
ples are shown in Table 2. The average OD 260/280 ratios 
for adult and for cord blood samples were 2.12  ±  0.01 
and 2.10  ±  0.02, respectively, indicating RNA of good 
quality (Table  2). There are no significant differences 
Table 1 Overview of the five RNA isolation protocols
a The kit supplier is Life Technologies, Norway
b The kit supplier is Norgen Biotek Corp, Canada
c All RNA species can be simultaneously isolated according to the manufacturer’s protocol
RNA isolation 
protocol
RNA isolation kit name RNA processing 
method






MagMAX™ for Stabilized Blood
Tubes RNA Isolation Kit, compatible with 
Tempus™ Blood
RNA Tubes
Semi-automated Magnetic beads based RNA purifi-
cation system
Yes
MagMAX manuala MagMAX™ for Stabilized Blood
Tubes RNA Isolation Kit, compatible with 
Tempus™ Blood
RNA Tubes
Manual Magnetic beads based RNA purifi-
cation system
Yes
Norgenb Preserved Blood RNA Purification Kit I (for 
use with Tempus Blood RNA Tubes)
Manual Column-based RNA purification 
systems:resin as the separation 
matrix
Yes
Tempus Spina Tempus™ Spin RNA Isolation Kit Manual Column-based RNA purification 
systems:silica membrane
No































Fig. 1 Comparison of RNA yields for the adult and cord blood 
samples collected in Tempus tubes. The RNA yield from adult blood 
samples (n = 12 Tempus tubes per protocol, n = 11 Tempus tubes for 
the Tempus 6-port protocol) and the RNA yield from cord blood sam-
ples (n = 3 Tempus tubes per protocol, except the ABI system, where 
n = 6 Tempus tubes). *The RNA yields from cord blood samples were 
significantly higher than for adult blood samples, and **the RNA 
yields obtained from cord blood samples using the two MagMAX 
protocols were significantly higher than the RNA yields obtained 
using the other three protocols (p < 0.05). Each bar represents the 
average RNA yield and the error bars indicate ± SE
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between the RNA isolation protocols, and the OD 
260/280 ratios for the samples were within an acceptable 
range of high-quality RNAs. However, the average OD 
260/230 ratios from adult blood samples isolated with the 
MagMAX manual and the Norgen protocols were signifi-
cantly lower (p < 0.05) than the OD 260/230 ratios from 
samples isolated with the other protocols (Table 2a). The 
reason for the observed differences is unclear. High salt 
content in the elution buffer may have more influence 
on the OD 260/230 ratios when the RNA amount is low. 
This difference was not observed for the cord blood sam-
ples, for which the average OD 260/230 ratios were above 
2.0 (Table 2b), indicating good quality RNA.
The RNA integrity, expressed as RIN values, of the 
RNA samples from each RNA isolation protocol, was 
calculated using the Bioanalyzer (Table  2). The average 
RIN value for each protocol for both adult blood and 
cord blood samples was around seven or higher, which 
reflects high-quality RNA; RIN values above seven are 
considered acceptable for most gene expression pro-
filing methods [23, 25, 27]. However, there were some, 
but not significant, differences in the average RIN val-
ues between the protocols. For adult blood samples, 
the RNA samples isolated using Tempus Spin had the 
highest average RIN values (8.97  ±  0.05) and samples 
isolated using MagMAX manual had the lowest average 
RIN values (7.20 ± 0.11) (Table 2a). For cord blood sam-
ples, the RNA samples isolated using Tempus 6-port had 
the highest average RIN values (8.37 ± 0.38), while sam-
ples isolated using Tempus Spin had the lowest average 
RIN values (7.13 ±  0.13) (Table 2b). The observed RIN 
values were comparable between the protocols and they 
were within the range of the RIN values reported in our 
previous studies [19, 20].
The RNA transcript stability and potential alteration of 
the transcript level for six genes and for 13 miRNAs were 
investigated by qPCR. The names of the investigated six 
mRNAs and 13 miRNAs are presented in Additional 
file  1. The six genes were selected based on our previ-
ous studies [19, 20], while the 13 miRNAs were selected 
based on literature search [21, 22] and their expression in 
blood samples. The interference of the high percentage of 
globin transcripts from red blood cells (RBC)—constitut-
ing ~70 % of the whole blood mRNA—may decrease the 
sensitivity of detecting less abundant mRNA transcripts, 
particularly in the microarray and next-generation 
sequencing technologies [28, 29]. We evaluated whether 
low abundant RNA transcripts, i.e., transcripts with Cq-
values above 30 cycles, could be detected in blood-RNA 
samples isolated using the five blood-RNA isolation pro-
tocols. Low abundant mRNA and miRNA transcripts 
were detected in all analyzed samples, and the results are 
presented in Additional file 1.
For mRNA transcript stability, the non-normalized raw 
Cq-values for the six genes from adult and cord blood 
samples isolated with the five RNA isolation protocols 
are presented in Tables 3 and 4, respectively. Differences 
in the raw Cq-values between the RNA isolation proto-
cols for each gene were small. The variations in the raw 
Cq-values were evaluated by calculating the coefficient 
of variation (CV) of each gene for each protocol, and 
the CV are presented in Tables 3 and 4, respectively. For 
adult blood samples, the variations in the CVs within a 
protocol and between protocols were small; the CVs 
Table 2 Comparison of RNA QC using five RNA isolation protocols
* RNA extracted with MagMAX manual and Norgen protocols have significantly lower OD 260/230 ratio compared to RNA from the other protocols, p < 0.05
RNA isolation protocol RIN value OD 260/280 ratio OD 260/230 ratio Number of Tempus tubes
(a) Adult blood
 MagMAX semi-automated 7.85 ± 0.13 2.09 ± 0.01 1.97 ± 0.05 12
 MagMAX manual 7.20 ± 0.11 2.12 ± 0.01 1.19 ± 0.12* 12
 Norgen 7.36 ± 0.12 2.12 ± 0.02 1.76 ± 0.07* 12
 Tempus spin 8.97 ± 0.05 2.09 ± 0.01 2.08 ± 0.01 12
 Tempus 6-port 8.38 ± 0.08 2.20 ± 0.06 2.02 ± 0.05 11
 Average 7.93 ± 0.10 2.12 ± 0.01 1.80 ± 0.05 59
(b) Cord blood
 MagMAX semi-automated 7.47 ± 0.22 2.09 ± 0.03 2.01 ± 0.09 3
 MagMAX manual 7.73 ± 0.47 2.12 ± 0.01 2.14 ± 0.02 3
 Norgen 8.23 ± 0.33 2.11 ± 0.01 2.07 ± 0.04 3
 Tempus spin 7.13 ± 0.13 2.10 ± 0.01 2.11 ± 0.01 3
 Tempus 6-port 8.37 ± 0.38 2.10 ± 0.01 2.10 ± 0.02 6
 Average 7.88 ± 0.19 2.10 ± 0.02 2.09 ± 0.05 18
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ranged from 0.8 to 3.0 % (Table 3). For cord blood sam-
ples, the variations in the CVs within a protocol and 
between protocols were also small; the CVs ranged from 
0.4 to 7.5  % (Table  4). The average CV value of the IL8 
gene isolated with the Norgen protocol had the highest 
CV value (CV = 7.5 %) (Table 4); the observed variabil-
ity could not be explained from the RNA quality param-
eters of RNA samples isolated with Norgen protocol. 
Nevertheless, the calculated CV values for adult and 
cord blood samples were less than 10  % for all samples 
indicating very low variability (Tables 3, 4). The raw Cq-
values were then normalized by the average of two sta-
bly expressed reference genes (18S rRNA and GAPDH) 
(Additional file  2). The normalized Cq-values (∆Cq-val-
ues) of the samples isolated with the new protocols were 
compared with the ∆Cq-values of samples isolated using 
the Tempus 6-port protocol (reference sample), generat-
ing fold differences (Fig.  2). This comparison was done 
since the Tempus 6-port protocol is a well-established 
RNA isolation protocol at the NIPH Biobank [19, 20]. For 
adult blood samples, the differences between the relative 
transcript levels from samples isolated using MagMax 
semi-automated and manual, Tempus Spin and Norgen 
protocols were very small when compared to samples 
isolated using Tempus 6-port, and the differences were 
less than two-fold (Fig.  2a). For cord blood samples, 
the relative transcript levels showed some differences 
(Fig. 2b); however, the transcript level changes were well 
within ±  twofold, except for the transcript levels of IL8 
and MYC genes for the Tempus Spin protocol and the 
transcript level of MYC gene for the MagMax manual 
protocol (Fig. 2b). The reasons for the observed variable 
effects of RNA isolation protocols on RNA transcript sta-
bility of these genes are unclear. IL8 and MYC had high 
average Cq-values above 30, particularly for the cord 
blood samples. The observed variability with high Cq-
values is typical for the qPCR process and the variability 
increases especially in low abundant transcripts with few 
templates [20]. Therefore, the observed differences in the 
relative transcript levels of IL8 and MYC genes are most 
likely associated with the qPCR process and may be not 
related to the RNA isolation protocols.
Tempus 6-port and the Tempus Spin kits are not opti-
mized for isolation of small RNAs (<200 nucleotides) 
and the supplier of these kits did not recommend using 
these two kits for small RNAs isolation. We therefore 
Table 3 Raw Cq-value and CVs (coefficients of variation) for adult blood samples
CVs are shown in italics; the overall averaged CVs range between 1.5 and 2.8 %
RNA isolation protocol CDKN1A FOS IL1B IL8 MYC TP53
MagMax semiautomated
 Average 30.5 26.9 28.4 30.4 29.1 28.3
 SD 0.7 0.2 0.8 0.3 0.4 0.4
 % CV 2.1 0.8 3.0 1.1 1.3 1.3
MagMax manual
 Average 30.1 26.5 27.9 30.0 28.8 27.8
 SD 0.7 0.3 0.7 0.3 0.4 0.3
 % CV 2.5 1.2 2.6 1.1 1.2 1.0
Norgen
 Average 30.7 26.6 28.2 30.2 29.9 28.7
 SD 0.7 0.4 0.8 0.4 0.4 0.4
 % CV 2.3 1.4 2.7 1.2 1.3 1.3
Tempus spin
 Average 29.4 26.1 27.9 29.5 28.9 27.8
 SD 0.7 0.3 0.8 0.4 0.3 0.4
 % CV 2.4 1.1 2.8 1.3 1.2 1.4
Tempus 6-port
 Average 29.9 26.4 28.0 29.9 29.1 28.0
 SD 0.8 0.2 0.7 0.3 0.3 0.3
 % CV 2.5 0.8 2.4 1.0 1.1 1.0
Overall average
 Average 30.1 26.5 28.1 30.0 29.2 28.1
 SD 0.9 0.4 0.8 0.5 0.5 0.5
 % CV 2.8 1.5 2.8 1.5 1.8 1.7
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evaluated the stability of 13 miRNA transcripts from the 
RNA samples isolated using the three RNA isolation pro-
tocols optimized for simultaneous isolation of all RNA 
species; MagMAX semi-automated, MagMAX manual, 
and Norgen protocols. The non-normalized raw Cq-val-
ues and the CV values for adult and cord blood samples 
of the 13 miRNAs are presented in Fig.  3a–d, respec-
tively. There were some differences in the raw Cq-values 
of the 13 miRNAs between the RNA isolation protocols 
(Fig.  3a, b). For both adult and cord blood samples, the 
CVs between protocols were not higher than the variabil-
ity within a protocol (i.e., the variability between donors 
within a protocol); the CVs ranged from 4.5 to 18.8  % 
for adult blood samples and from 1.7 to 10.9 % for cord 
blood samples, respectively (Fig.  3c, d). For adult blood 
samples, the CVs for the miRNA transcripts from RNA 
samples isolated with Norgen protocol were in general 
slightly lower than with the other two protocols (Fig. 3c). 
An interesting general finding was that cord blood sam-
ples had a narrower CV range than adult blood samples 
(Fig. 3c, d), and most of the miRNA transcripts had CV 
values lower than 10 %, except the CV for hsa-miR451 for 
all three protocols and the CV for hsa-let-7a for the Mag-
Max manual protocol (Fig. 3d). It has been reported that 
average CV values lower than 25 % are typically observed 
for stably expressed reference genes in relatively homo-
geneous samples [20, 30]. In this study, blood samples 
from several human donors were analyzed, and usually 
high variations are observed from heterogeneous sam-
ples such as human samples. The calculated CVs for both 
adult and cord blood samples were less than 20 % for all 
RNA isolation protocols (Fig.  3c, d), and these results 
suggest that the RNA isolation protocols had similar 
effects on the miRNA transcript stabilities (Fig. 3c, d).
The raw Cq-values of the 13 miRNAs were then nor-
malized by the average of three stably expressed reference 
small nuclear RNAs (RNU6, RNU43 and RNU1) (Addi-
tional file  3), and the average log2 normalized relative 
quantity (log2- NRQ) values are presented in Figs. 4a, 5a. 
For adult blood samples, some differences in the average 
transcript levels of some miRNAs were observed between 
the three RNA isolation protocols (Fig. 4a). The most pro-
nounced difference was observed between Norgen pro-
tocol on one hand and the other two MagMax protocols 
Table 4 Raw Cq-value and CVs (coefficients of variation) for cord blood samples
CVs are shown in italics; the overall averaged CVs range between 1.8 and 3.9 %. The average CV value of the IL8 gene isolated with the Norgen protocol had the 
highest CV value (CV = 7.5 %) and shown in bolditalics
RNA isolation protocol CDKN1A FOS IL1B IL8 MYC TP53
MagMax semiautomated
 Average 32.5 28.0 29.8 32.2 29.9 29.5
 SD 0.5 0.9 0.6 1.2 0.3 0.2
 % CV 1.4 3.2 2.0 3.8 1.1 0.7
MagMax manual
 Average 32.0 28.2 29.5 32.6 29.4 29.1
 SD 0.2 0.3 0.3 0.4 0.2 0.2
 % CV 0.6 1.1 1.1 1.3 0.7 0.6
Norgen
 Average 32.7 28.2 29.7 31.5 30.0 29.6
 SD 0.6 1.4 1.0 2.4 0.3 0.5
 % CV 1.8 5.1 3.5 7.5 1.1 1.6
Tempus spin
 Average 31.8 28.0 28.8 31.2 29.3 28.7
 SD 0.2 0.3 0.2 0.4 0.1 0.2
 % CV 0.7 1.2 0.7 1.4 0.4 0.7
Tempus 6-port
 Average 33.0 29.0 30.1 32.8 31.0 29.9
 SD 0.6 0.5 0.3 0.4 0.8 0.4
 % CV 1.8 1.8 0.9 1.3 2.5 1.2
Overall average
 Average 32.5 28.4 29.7 32.2 30.1 29.5
 SD 0.6 0.9 0.7 1.3 0.8 0.5
 % CV 2.0 3.0 2.3 3.9 2.8 1.8
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on the other hand (Fig.  4a). This was not an unexpected 
finding, since MagMax semi-automated and manual pro-
tocols share similar kit components. Nevertheless, high 
and significant correlations between the log2-NRQ val-
ues of the 13 miRNAs between the MagMax semi-auto-
mated and the MagMax manual protocols (r  =  91.3  %; 
p < 0.001), between the MagMax semi-automated and the 
Norgen protocols (r = 92.2 %; p < 0.001), and between the 
MagMax manual and the Norgen protocols (r =  91.1  %; 
p < 0.001), were observed (Fig. 4b–d).
Similar conclusions can be drawn for cord blood 
samples (Fig.  5a), where the average log2-NRQ-val-
ues of some miRNAs were differentially expressed 
between the three RNA isolation protocols (Fig.  5a). 
As with adult blood samples, high and significant cor-
relations were observed between the three RNA isola-
tion protocols (Fig.  5b–d). The correlation between the 
MagMax semi-automated and the MagMax manual 
protocols was r =  95.0  %; p  <  0.0001, whereas the cor-
relation between the Norgen protocol and the MagMax 
semi-automated or the MagMax manual protocols were 
r = 94.0 %; p < 0.0001 and r = 98.0 %; p < 0.0001, respec-
tively (Fig. 5b–d). Taken together, the small variability in 
the raw Cq-values and the high correlation of NRQ-val-
ues demonstrate that the three RNA isolation protocols 
could be used interchangeably.
Among the two well-established commercially available 
blood-RNA stabilizing platforms (Tempus Blood RNA 
and PAXgene™ Blood RNA system) where blood is drawn 
directly into a tube containing RNA stabilizing reagents, 
the PAXgene™ Blood RNA system is an established sys-
tem for the isolation and analysis of small RNAs (particu-
larly, miRNAs) [31, 32]. A literature search in the publicly 
available databases revealed no per-reviewed reports on 
small ncRNAs quality and transcript stability from cord 
blood samples collected in the Tempus tubes. This report 
is therefore the first systematic evaluation of the stability 
of small ncRNA (particularly, miRNAs) in cord samples 
collected in Tempus tubes.
Other aspects to consider when choosing a new 
method are cost (cost per sample) and sample processing 
time. We calculated the cost per sample for each protocol 
and the RNA processing time (i.e., RNA isolation time 
plus hands-on-time, including centrifugation, vortexing, 
optional DNase treatment step and incubating time) for 
six Tempus tubes (Table 5). Six Tempus tubes were ana-
lyzed because only six samples can be processed on the 
Tempus 6-port protocol at the same time. There were 
differences in the cost per sample between the protocols; 
Norgen is the cheapest kit whereas Tempus 6-port is the 
most expensive kit (Table 5). The RNA processing cost is 
particularly important for large-scale human biobanks. 
At NIPH Biobank, more than 50,000 adult and cord 
blood samples were collected in the Tempus tubes and 
stored. It is likely that RNA will be isolated from all of 
these blood samples. If all the 50,000 blood samples are 
processed, a difference by only one US dollar in a sample 
processing cost between two protocols will be large. It is 
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 b Cord blood
CDKN1A FOS IL1B IL8 MYC TP53
Fig. 2 RNA transcript levels of six target genes from adult and cord 
blood samples. RNA isolated from adult and cord blood samples 
using five different protocols and analyzed by qPCR. a Relative 
transcript levels of six genes from adult blood samples collected in 
Tempus tubes (n = 11–12 Tempus tubes for each protocol). b Relative 
transcript levels of six genes from cord blood samples collected in 
Tempus tubes (n = 3–6 Tempus tubes for each protocol). The Tempus 
6-port samples were used as reference samples (calibrators) and all 
other samples were compared against the reference samples. Each 
bar represents the average log2-transformed fold change values; fold 
change = 2−∆∆Cq. The error bars indicate ± SE and the stippled lines 
indicate ± twofold
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before a final choice of RNA isolation protocol. We noted 
some differences in the RNA processing time between 
the protocols. Semi-automation of the RNA isolation 
process did not significantly reduce the overall sample 
processing time (Table 5).
Finally, we evaluated the possibility of detecting 
miRNA transcripts from RNA samples isolated using 
the Tempus spin and the Tempus 6-port protocols. The 
supplier of the two kits did not recommend the use of 
these kits for isolation of small RNAs (<200 nucleotides). 
We therefore analyzed pooled RNA samples resulting 
from the two protocols. Each pooled RNA sample was 
divided into three equal aliquots for each adult and cord 
blood samples; the transcript levels of the 13 miRNAs 
were then analyzed by qPCR (Fig.  6). The average raw 
Cq-values for the 13 miRNAs obtained both from adult 
and cord blood samples from the Tempus spin and the 
Tempus 6-port RNA isolation protocols were within 
the range of the average Cq-values obtained from RNA 
samples from the other three protocols (MagMax semi-
automated, MagMax manual, and Norgen protocols) 
optimized for small RNA isolation (Fig.  6a, b). Even 
though these two protocols were optimized for isolation 
of large RNA molecules (i.e., >200 nucleotides) and not 
for RNA of a smaller size range, it seems that compara-
ble miRNA transcript levels can be detected from these 
protocols (Fig. 6a, b). The presence of one peak for each 
miRNA amplicon during melting curve analysis indicates 
that a single amplicon has been generated by the qPCR 
assay. We observed one single peak for each miRNA from 
the RNA samples isolated with the Tempus spin and the 



























































































































































































































































































































































































Fig. 3 Non-normalized raw Cq-value and coefficients of variation of 13 miRNAs. RNA isolated from adult and cord blood using three different RNA 
isolation protocols optimized for simultaneous isolation of all RNA species and analyzed by qPCR. The non-normalized raw Cq-values for adult blood 
(n = 12 Tempus tubes) and cord blood (n = 3 Tempus tubes) samples collected in the Tempus tubes. a Average non-normalized raw Cq-values 
for adult blood samples; b the average non-normalized raw Cq-values for cord blood samples. The error bars indicate ± SE. There are no significant 
differences in the raw Cq-values between the three RNA isolation protocols. The coefficients of variation (CV) of the average raw Cq-values were 
calculated for adult and cord blood samples for each RNA isolation protocol for the 13 miRNAs. c CVs for adult blood samples (ranging from 4.5 to 
18.8 %); d CVs for cord blood samples (ranging from 1.7 to 10.9 %). CV of 10 and 20 % is indicated by stippled lines. Each point represents the aver-
age CV of samples for one miRNA from one Tempus tubes from one protocol
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amplicon peak for each miRNA was similar to the peak 
observed from the RNA samples isolated with the other 
three protocols indicating the absence of non-specific 
amplification. Successful detection of miRNA transcripts 
from RNA samples isolated with the Tempus spin and 
the Tempus 6-port protocols was unexpected and repre-
sents an interesting finding; however, these two kits are 
not among the cheapest blood-RNA isolation protocols 
optimized for blood samples collected in the Tempus 
tubes (Table 5).
Conclusions
Our results indicate that high-quality total RNA, includ-
ing miRNAs, suitable for mRNA and miRNA expression 
profile analysis, can be obtained from blood samples col-
lected into Tempus tubes using different commercially 
available RNA isolation protocols. A balanced considera-
tion of the RNA yield, quality, transcript stability, sample 
processing time and cost will have a large influence on the 
choice of RNA isolation protocol. The integrity and purity 
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Fig. 4 Log2-NRQ values for 13 miRNAs for adult blood samples. The normalized relative quantity values [NRQ = 2−ΔCq(sample); where the ΔCq 
(sample) = Cq (miRNA) − Cq (internal control)]) of 13 miRNAs from adult samples collected in Tempus tubes (n = 12 Tempus tubes for adult blood). 
a Log2-transformed NRQ-value of 13 miRNAs for the three RNA isolation protocols. Each bar represents the log2-transformed NRQ values and the 
error bar indicates ± SE; b correlation between MagMax semi-automated and manual protocols; c correlation between MagMax semi-automated 
and Norgen protocols; d correlation between MagMax manual and Norgen protocols. There are significant (p < 0.001) correlations between the 
NRQ-values of the three protocols. Each point represents the average of log2-NRQ values of three technical replicates from one Tempus tube, i.e., 13 
miRNAs × 12 blood samples from 12 Tempus tubes
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protocols were comparable and they were of high quality. 
In general, the mRNA transcript levels of the six studied 
genes were relatively stable. The different RNA isolation 
protocols did not show a significant influence on their 
transcript stability. However, the miRNA transcript lev-
els were slightly affected by the different RNA processing 
methods, although the 13 miRNAs had similar expression 
direction and their levels were within the same order of 
magnitude. The most unexpected and interesting finding 
was detection of miRNA transcripts from RNA samples 
isolated with the Tempus spin and the Tempus 6-port 
protocols, originally not optimized for isolation of small 
RNAs. Overall, a satisfactory amount of high-quality RNA 
was obtained from all five protocols suitable for mRNA 
and miRNA expression profiling; the Tempus blood 
RNA system seems to be robust and flexible and not to 
be dependent on one specific RNA isolation method. This 
is good news for large-scale human biobanks such as the 
NIPH Biobank, where tens of thousands of samples are 



































































































































































Fig. 5 Log2-NRQ values for 13 miRNAs for cord blood samples. The normalized relative quantity values [NRQ = 2−ΔCq(sample); where the ΔCq 
(sample) = Cq (miRNA) − Cq (internal control)]) of 13 miRNAs from cord samples collected in the Tempus tubes (n = 3 Tempus tubes for adult 
blood). a Log2-transformed NRQ-value of 13 miRNAs for the three RNA isolation protocols. Each bar represents the log2-transformed NRQ values 
and the error bar indicates ± SE; b correlation between MagMax semi-automated and manual protocols; c correlation between MagMax semi-auto-
mated and Norgen protocols; d correlation between MagMax manual and Norgen protocols. There are significant (p < 0.001) correlations between 
the NRQ-values of the three protocols. Each point represents the average of log2-NRQ values of three technical replicates from one Tempus tube, 
i.e., 13 miRNAs × 3 blood samples from 3 Tempus tubes
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Methods
Sample collection and experimental design
Whole blood samples were collected from four healthy, 
consenting adult volunteers among the NIPH staff. 
Umbilical cord blood samples were collected from six 
newborns whose mothers had given their informed con-
sent to participate in MoBa. The samples were collected 
into Tempus tubes (3  ml blood per tube) according to 
the manufacturer’s instructions (Life Technologies, Nor-
way). The Tempus tubes were from the same lot number. 
In total, 59 tubes from four adults and 18 tubes from six 
newborns were collected. The tubes were randomized 
for each donor and labelled with unique numbers. Each 
Tempus tube was considered as an independent biologi-
cal sample. The adult blood samples were kept at room 
temperature for 2 h before freezing at −20 °C overnight 
and then transferred to −80  °C until processing. The 
cord blood samples were collected at the maternity unit 
at Ullevål University Hospital and shipped to NIPH at 
ambient temperature within 1  day, and then handled in 
the same way as samples from the adults. The cord blood 
samples are part of blood samples collected specifically 
for RNA QC for cord blood samples stored at MoBa. For 
each protocol, 12 adult blood samples and 3 cord blood 
samples were analyzed, except for the Tempus 6-port 
protocol, where 11 adult blood and 6 cord blood samples 
were analyzed. With each Tempus tube considered as an 
independent biological sample, the analysis of in total 77 
Tempus tubes should provide a good estimate of the qual-
ity and stability of the samples. MoBa has obtained its 
license from the Norwegian Data Inspectorate (01/4325) 
and the MoBa project is approved by the Regional Com-
mittee for Medical Research Ethics (S-97045, S-95113); 
participants gave their informed consent.
RNA extraction protocols
Total RNA from blood collected in Tempus tubes was 
extracted using four different commercial kits: MagMAX 
for Stabilized Blood Tubes RNA Isolation Kit (compat-
ible with Tempus Blood RNA Tubes) (Life Technologies, 
Table 5 RNA isolation protocols costs and sample processing times
a The cost of kits and other consumables, in US Dollars
b Price does not include the cost of MagMAX™ Express 96 deep-well Magnetic Particle Processor for MagMax semi-automated, the cost of 96 well Magnetic-Ring 
Stand for MagMax manual, and the cost of ABI PRISM™ 6100 Nucleic Acid PrepStation for Tempus 6-port
c RNA processing time for six samples in the authors’ laboratory—it includes RNA isolation time and hands-on-time such as centrifugation, vortexing, incubation etc
RNA isolation protocol Cost per samplea RNA processing time for six samples (min)c
MagMAX semi-automated 18.5b 90
MagMAX manual 12.7b 120
Norgen 10.5 90
Tempus Spin 14.0 90
































































































 Adult blood 
































































































 Cord blood 
Tempus 6-port Tempus spin
a
b
Fig. 6 Non-normalized raw Cq-value for Tempus spin and 6-port. 
The non-normalized raw Cq-values for adult blood and cord blood 
samples collected in the Tempus tubes. a Average non-normalized 
raw Cq-values for adult blood samples (three replicates from pooled 
RNA samples per protocol); b average non-normalized raw Cq-values 
for cord blood samples (three replicates from pooled RNA samples 
per protocol). The error bars indicate ± SE
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Norway); Tempus Spin RNA Isolation kit; Tempus 6-port 
RNA isolation kit on an ABI PRISM TM 6100 Nucleic Acid 
Prep Station (Life Technologies, Norway); and finally, Pre-
served Blood RNA purification kit 1 (for use with Tempus 
Blood RNA Tubes) (Norgen Biotek Corp, Canada). For the 
MagMAX kit, RNA was isolated according to the manu-
facturer’s protocol which included a TURBO DNase and 
protease step. Both a manual and a semi-automated pro-
tocol were used for the isolation of RNA. For the manual 
protocol, samples were processed using 1.5-ml microfuge 
tubes on a magnetic stand; for the semi-automated proto-
col, a 96-well processing plate on a MagMAX Express-96 
Magnetic Particle Processor was used. In the washing steps, 
twice the amount of washing solution, e.g. 300 µl, was used. 
Tempus tubes were processed using Tempus 6-port RNA 
isolation kit as previously described. For the Norgen Pre-
served Blood RNA Purification kit I, the Tempus 6-port 
RNA isolation kit, and the Tempus Spin RNA isolation kit, 
optional DNase treatments were included in accordance 
with each manufacturer’s protocol. The isolated total RNA 
was stored at −80  °C until analysis in elution buffers sup-
plied with each respective RNA isolation kit.
RNA QC
The concentration of extracted total RNA was measured 
using NanoDrop ND-8000 spectrophotometer (Thermo 
Scientific, Norway). RNA purity was estimated by exam-
ining the OD 260/280 and the OD 260/230 ratios. RNA 
integrity was found using the Eukaryote total RNA 6000 
Nano LabChip kit and Eukaryote total RNA Nano assay 
on an Agilent 2100 Bioanalyzer according to the manu-
facturer’s instructions (Agilent Technologies, Norway). 
RNA integrity numbers (RIN) from 1 to 10 (low to high 
RNA quality) were calculated using the 2100 Expert soft-
ware (Agilent Technologies, Norway).
Quantitative real time PCR (qPCR) assay
The cDNA synthesis was performed with 100  ng total 
RNA from samples as template, using the High Capac-
ity cDNA Reverse Transcription Kit (Life Technologies, 
Norway) according to the manufacturer’s protocol. The 
amplification reactions were carried out in a DNA Engine 
DYAD Peltier Thermal Cycler (BioRad, Norway) with the 
following steps: 10 min at 25 °C, 2 h at 37 °C and finally, 
5 min at 85 °C. For the microRNA (miRNA) study, cDNA 
from 1 µg of RNA was synthesized using the miScript II 
RT kit including 5× miScript HiSpec Buffer (for selec-
tive conversion of mature miRNA into cDNA) accord-
ing to the manufacturers protocol (Qiagen, Norway). A 
no reverse transcriptase control (NRT) was included and 
samples were incubated at 37 °C for 60 min and 95 °C for 
5 min. All cDNA samples were stored at −20 °C prior to 
gene expression analysis.
Quantitative real-time PCR (qPCR) was carried out in 
96-well PCR plates using TaqMan Fast Universal PCR Mas-
ter Mix, No AMpErase UNG, according to the manufac-
turer’s protocol (Life technologies, Norway) on a Fast 7500 
Real Time PCR system (Life Technologies, Norway). The 
following cycling conditions were used: an enzyme acti-
vation step at 95 °C for 20 s, and then 40 cycles of anneal-
ing and extension steps at 95 °C for 3 s and 60 °C for 30 s, 
respectively. Serial dilutions of cDNA were prepared to 
determine the appropriate cDNA dilution. A 1:10 dilution 
of cDNA from each Tempus tube was run in triplicate for 
each gene of interest. Non-template controls (NTC) were 
included in all assays. Transcript levels for the following six 
genes were measured as described in our recent study [20], 
applying commercial primers and probe assays from Life 
Technologies: CDKN1A (PN: Hs00355782_m1), FOS (PN: 
Hs00170630_m1), IL1B (PN: Hs00174097_m1), IL8 (PN: 
Hs001700174103_m1), MYC (PN: Hs00153408_m1) and 
TP53 (PN: Hs00153340_m1), 18S rRNA (PN: Hs99999901) 
and GAPDH (PN: Hs9999905_m1). The geometric aver-
age of the two reference genes, 18S rRNA and GAPDH was 
used for normalization. The six genes were selected based 
on our recent study [19] and literature search [33, 34], with 
mRNA transcript abundance from low to high abundant 
targets (Additional file 1).
MicroRNA specific qPCR was carried out in 384-well 
PCR plates using miScript SYBR Green PCR Kit accord-
ing to the manufacturer’s protocol (Qiagen, Norway) on a 
CFX384 Touch™ Real-Time PCR Detection System (Bio-
Rad, Norway). Serial dilutions of cDNA were prepared to 
determine the optimal dilution. A 1:10 dilution of cDNA 
from each Tempus tube was run in triplicate for each 
gene of interest. The cycling program included an initial 
enzyme activation step at 95 °C for 15 min, and then 40 
cycles of denaturation, annealing and extension steps at 
94 °C for 15 s, 55 °C for 30 s and 70 °C for 30 s, respec-
tively. The melting curve (Tm) analysis was included 
in each run. Non-template controls (NTC) and non-
reverse transcriptase controls (NRT) were included in 
each run. The expression levels of the following 13 miR-
NAs (hsa-let-7a, hsa-miR-16, hsa-miR-20a, hsa-miR-21, 
hsa-miR-26a, hsa-miR-34a, hsa-miR-451, hsa-miR-93, 
hsa-miR-103, hsa-miR-126, hsa-miR-191, hsa-miR-192, 
hsa-miR-423-3p), and three small nuclear RNAs (snRNA; 
RNU6, RNU43 and RNU1), were measured. These miR-
NAs were selected based on their expression abundance 
in blood and literature search [21, 22].
Data analysis
The quantification cycle (Cq) values were recorded with 
SDS v1.3 software (Life Technologies, Norway) or CFX 
Manager™ Software (Bio-Rad, Norway). The raw Cq-
values were then exported into Excel-files and analyzed 
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by the comparative Cq-method [35, 36] using 18S rRNA 
and GAPDH as reference genes (internal control) for 
mRNA transcript level analysis, while RNU6, RNU43 
and RNU1 were used as reference genes for miRNA 
transcript level analysis. Prior to normalization, the raw 
data (Cq-values) generated from qPCR experiments 
were pre-processed to ensure that measurements at 
low levels were well within the linear area of detection; 
Cq-values radically different from other technical rep-
licates were classified as outliers and excluded. In addi-
tion, all Cq-values above 35 were considered beyond 
the limit of detection (LOD) and coded as missing val-
ues, because Cq-values above 35 cycles are in general 
not reliable. Target genes were normalized by the aver-
age of stably expressed reference genes, [this is given 
by ΔCq; where ∆Cq (sample) = Cq (target gene) − Cq 
(reference genes)]. The ΔΔCq values were generated by 
subtracting the ΔCq-value for the reference samples 
(calibrators; Tempus 6-port) from the ΔCq-value for 
the samples [∆∆Cq  =  ∆Cq (sample)  −  ∆Cq (calibra-
tor); fold change =  2−∆∆Cq]. For miRNA data, the tar-
get miRNAs were normalized by the average of three 
stably expressed reference genes (RNU6, RNU43 and 
RNU1); this is given by ΔCq; where ∆Cq (sample) = Cq 
(target miRNA)  −  Cq (reference snRNAs). The ∆Cq 
values were then presented as normalized expression 
(NRQ = 2−∆Cq). The NRQ values were then log2-trans-
formed in order to make the values symmetrical around 
zero. The reference gene stability was evaluated and 
results are presented in Additional files 2 and 3.
Statistical analysis
Statistical analysis of RNA yield, purity, integrity and 
∆Cq-values was carried out by one-way analysis of vari-
ance (ANOVA), followed by post hoc Tukye’s HSD 
(honest significant difference) tests to allow for multi-
ple comparisons or by non-parametric Kruskal–Wallis 
test. Normal distribution and equality of variances were 
evaluated using the Shapiro–Wilk normality test and 
the Levene’s or Bartlett test of homogeneity of variance. 
The correlations of the log2-NRQ values of the 13 miR-
NAs between the three RNA isolation protocols (Mag-
Max semi-automated, MagMax manual and Norgen) 
were analyzed by Pearson or Spearman statistics and the 
regression lines were generated using GraphPad Prism 
5.0 (GraphPad Software, Inc., USA). Statistical analy-
ses were performed using the R statistical programming 
environment (version 3.1.1), and results with p  <  0.05 
were accepted as statistically significant. The data are 
presented as mean  ±  SE. The coefficient of variation 
(CV) of the non-normalized raw Cq-value for each gene 
was calculated by dividing the mean Cq-value with the 
standard deviation. CV, expressed as a percentage, was 
used for computing the degree of variation in the average 
Cq-values of the RNA isolation protocols.
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